NeuroMab™ Anti-NOTCH3 Antibody(NRP-0422-P1850)

Figure 1 shows Western blot analysis of Notch3 positive and negative cell lines using the D11B8 antibody.

Figure 2 Intracellular trafficking of anti-Notch3 antibody hu75-Alexa 488 and co-localization with pHrodo™ red dextran in MDA-MB-468 breast cancer cells at 5 hours (arrow), [C] anti-Notch3 antibody hu28- Cell membrane localization of DyLight650 and labeling of acidic vesicles in MDA-MB-468 breast cancer cells with pHrodo™ red dextran (intracellular spots) at hour 0, [D] intracellular trafficking of the anti-Notch3 antibody hu28-DyLight650 and association with Co-localization of pHrodo™ red dextran in MDA-MB-468 breast cancer cells at 8 hours (arrows) and [E] Pearson correlation coefficient indicating that hu28-DyLight650 and pHrodo™ red dextran fluorescently labeled in MDA-MB Overlap or colocalization degree time in -468 cells.

Figure 3 shows Western blot analysis of the S2 cleavage assay using anti-Notch3 hu28 and hu75 treated HCC2429 and MDA-MB-468 cells. MW = molecular weight.

Figure 4 shows that treatment of OVCAR3 ovarian cancer cells with anti-Notch3 hu28-vc0101 disrupts microtubules in mitotic cells (stained with anti-α-tubulin antibody), identified by phospho-histone H3 staining.

Figure 5 shows Western blot analysis of Notch3-ECD from xenografts harvested from 2-3 mice (M).

Figure 6 shows the efficacy of anti-Notch3 hu28-vc0101 and hu75-vc0101 at a dose of 3 mg/kg compared to cisplatin at a dose of 5 mg/kg in a 37622A1 NSCLC patient-derived xenograft model.

Figure 7 shows the efficacy of anti-Notch3 hu28-vc0101 in the MDA-MB-468 breast model.

Figure 8 shows the efficacy of anti-Notch3 hu28-vc6780 in the MDA-MB-468 breast model.

Figure 9 shows the efficacy of anti-Notch3 hu28-vc0101 in the OVCAR3 ovarian model.